Russell Abberley

Seaport Therapeutics

Eric Green

Seaport Therapeutics has appointed Eric Green as chief operating officer. Green brings over 25 years of experience to his new role. He most recently served as senior vice president, head of development programmes at Alnylam Pharmaceuticals. Previously, Green served at companies including Pfizer, Genzyme Transplant & Oncology and Infinity Pharmaceuticals.

Seaport Therapeutics

Michael Chen

Seaport Therapeutics has appointed Michael Chen as chief scientific officer. Chen, who is a co-founder of Seaport, brings extensive industry experience to his new position. He most recently served as the head of innovation at PureTech Health. Prior to this, Chen served as co-founder and head of research and development at Sonde Health.

Engitix Therapeutics

Matthew Edwards

Engitix has appointed Matthew Edwards as senior vice president of discovery sciences. Edwards brings extensive experience from working across a variety of senior positions to his new position. He joins from Johnson & Johnson, where he served as global head discovery and translational sciences. Prior to this, Edwards held senior positions at GSK and Novartis.

Engitix Therapeutics

Emma Huang

Engitix has appointed Emma Huang as vice president of data sciences. Huang holds in-depth experience in the development of novel therapies and solutions for patients. She most recently served as head of data sciences for interventional oncology at Johnson & Johnson. Prior to this, Huang also held positions at the Medical Research Council, Innovate for Health and CSIRO.

Kancera

Johan Schultz

Kancera has appointed Johan Schultz as vice president, research and development operations. Schultz brings more than three decades of experience in academic research in the pharmaceutical industry to his new role. He most recently served as project director at Kancera. Prior to this, he served as project manager and principal scientist at iNovacia.

Envision Pharma Group

Alistair Macdonald

Envision Pharma Group has appointed Alistair Macdonald to its board of directors. Macdonald has over three decades of biopharmaceutical and life sciences leadership experience. He currently serves as non-executive director at SEQENS Pharmaceutical Solutions, Klick and the Medicines Discovery Catapult. Prior to this, Macdonald served as chief executive officer at Syneos Health.

Vertex Pharmaceuticals

Jennifer Schneider

Vertex Pharmaceuticals has appointed Jennifer Schneider to its board of directors. Schneider has more than two decades of experience in the healthcare industry as a physician, scientist and healthcare executive. She co-founded and currently serves as chief executive officer of Homeward Health. Prior to this, she served as president and chief medical officer of Livongo Health.

Harness Therapeutics

Meenu Chhabra Karson

Harness Therapeutics has appointed Meenu Chhabra Karson as board chair. Karson brings over two decades of experience in the global biopharmaceutical industry to her new role. She serves as executive chair at Samsara Therapeutics and board director at MacroGenics. Prior to this, Karson held positions at companies including Novartism Proteostasis Therapeutics.